Physician profile
Bryan R Hyler
NPI 1811218092
$16,853.39
in general payments reported to CMS, 2019-2025
25 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 86% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,652 · 2020: $1,475 · 2021: $1,208 · 2022: $1,999 · 2023: $3,546 · 2024: $2,825 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,355 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,354.78 |
| Education | $165.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,072.81 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,983.10 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,967.29 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,894.96 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $1,737.68 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $1,221.88 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $997.04 | 2019-2022 | |
| Abbvie INC. | $947.19 | 2021-2025 | |
| Axsome Therapeutics, INC. | $744.06 | 2023-2025 | Auvelity |
| Allergan, INC. | $672.10 | 2019-2020 | |
| Indivior INC. | $441.92 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $437.76 | 2020-2025 | Fanapt |
| Lundbeck LLC | $272.48 | 2020-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $248.88 | 2020-2023 | Trintellix |
| Bausch Health US, LLC | $228.96 | 2020-2024 | Aplenzin |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $169.45 | 2024 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $165.09 | 2022-2023 | Quviviq |
| Corium, LLC | $160.23 | 2021-2023 | Azstarys |
| Acadia Pharmaceuticals INC | $118.71 | 2019 | |
| Lilly USA, LLC | $115.96 | 2025 | Zepbound |
| Biohaven Pharmaceutical Holding Company Ltd. | $86.28 | 2022 | |
| Tris Pharma INC | $68.30 | 2023 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $65.42 | 2022-2023 | Qelbree |
| Avanir Pharmaceuticals, INC. | $19.15 | 2021 | |
| Eisai INC. | $16.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Hyler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.